Intravenous leiomyomatosis (IVL) is a rare benigndisease that presents as a biologically aggressive tumor. Two hypotheses have been proposed in the literature regarding its etiology: it originates from neoplastic smooth muscle cellsof the uterus invading the veins of the reproductive system[6] or the proliferation of smooth muscle cells in the tunica media of blood vessels[7].Among the 11 patients reported in this paper, 8 (72.7%) had a history of uterine fibroids, and 5 (45.5%) had undergone myomectomy. Post-surgery, all patients were pathologically confirmed to have uterine fibroids. Furthermore, in 5 patients with lesions invading the internal iliac vein and beyond, the extension pattern was similar to the return path of parauterine/uterine veins, where the lesion extended from the uterine vein to the internal iliac vein, common iliac vein, inferior vena cava, and even reaching the right atrium. Based on the evidence discussed, it is considered that IVL originates from neoplastic smooth muscle cells of the uterus invading the veins of the reproductive system. A The literature suggests that HMGA2 protein expression along with the translocation of t12;14 q15;q24 is more common in patients with IVL[8], which may play an important role in allowing the invasion of leiomyomas into the vascular system.
IVL typically presents with nonspecific symptoms, and its diagnosis heavily relies on imaging, such as pelvic ultrasound, enhanced CT, and MRI. Pelvic ultrasound is the most convenient, minimally invasive, and widely used examination method for diagnosing gynecological diseases. In our experience, IVL lesions usually extend upward via the uterine vein, and tortuous and thickened parauterine/uterine veins can be observed under pelvic ultrasound in most patients. However, it's worth noting that pelvic ultrasound can only assess the pelvic veins, and its accuracy often depends on the experience of the sonographer. Enhanced CT or MRI is more helpful in evaluating the internal iliac-common iliac-inferior vena cava venous system, assessing the extent of the lesion, and determining operative procedures [9, 10]. Clinicians can interpret these images themselves, eliminating the need to rely solely on the sonographer's diagnosis. Due to resource limitations, CT/MR is not suitable for routine screening, and thus, pelvic ultrasound can be used for the initial screening of IVL. If pelvic ultrasound reveals uterine fibroids combined with tortuous and thickened parauterine/uterine veins in a patient, the possibility of IVL should be highly suspected, and further confirmation through enhanced CT or MR is necessary. Additionally, echocardiogram evaluation is often used to assess heart cavity lesions, and the mass in IVL is highly mobile and can be seen originating from the inferior vena cava[1, 11].
Out of the 11 patients, 6 (54.55%) had lesions limited to the parauterine/uterine area and were operated on via transabdominal or laparoscopic surgery, resulting in less intraoperative bleeding. However, 2 patients had lesions above the internal iliac vein, but not reaching the inferior vena cava, which significantly increased blood loss, necessitating blood transfusions. Nonetheless, these cases did not generally require ICU admission after surgery. Patients with lesions invading the internal iliac vessels or extending above experienced significantly higher perioperative blood loss, often requiring a large amount of blood preparation and ICU admission for further treatment after surgery. Two patients had residual lesions after surgery (including 1 patient with stage I lesion invading the internal iliac vein and 1 patient with stage III). Both patients showed disease progression during follow-up. Therefore, patients without lesions in the internal iliac vein and above have lower surgical risk, higher surgical resection rates, and a better prognosis.
IVL mostly occurs in premenopausal women [12], In this study, all 11 patients were premenopausal. It is generally considered an estrogen-dependent tumor due to the positive expression of estrogen and progesterone receptors in most cases, as revealed by immunohistochemistry[13]. Currently, the main treatment methods for IVL are surgery and anti-estrogen therapy[3–5, 9]. Anti-estrogen therapies reported in the literature include sBSO-based(Bilateral salpingo-oophorectomy) surgery[4]and Anti-estrogen hormonedrugs[14–16] (GnRH, Aromatase inhibitors, etc.), These treatments may involve preoperative adjuvant therapy to reduce the lesion size and facilitate surgery[4], as well as postoperative adjuvant therapy to lower the recurrence rate of the disease[14–16]. However, complete resection of the lesion remains crucial in preventing recurrence[12]. In this study, Case 10 underwent GnRHa therapy for six months before surgery, but no significant reduction in the lesion was observed during follow-up. Two patients with progressive disease (Case 7, Case 9) had residual disease one month after surgery, despite receiving GnRHa therapy for 6 months, indicating disease progression. One patient with stable disease (Case 9) experienced improvement after switching to letrozole, while another patient (Case 7) faced rapid disease progression due to preserved ovaries during surgery, necessitating bilateral resection of ovarian and venous lesions after recurrence. In contrast, Case 6 was not diagnosed with IVL before surgery, and an open myomectomy was performed for uterine fibroids. The lesion was completely removed, and no IVL lesions were found during intraoperative exploration. The patient received GnRHa therapy for 6 months, and no signs of disease recurrence were found during postoperative follow-up, eliminating the need for a second operation. Based on these experiences, complete resection of the lesion appears to be the most effective way to prevent IVL recurrence and progression.
It's important to acknowledge the limitations of this study. As IVL is a rare disease, our analysis is retrospective and based on a small number of cases. Additionally, most of the cases collected were at stage I, with no summary cases of stage IV. Further large-sample data or prospective studies are needed to confirm our conclusions.
In conclusion, intravenous leiomyomatosis (IVL) is most commonly found in premenopausal women with uterine masses. The majority of IVL lesions are confined to the pelvic cavity (Stage I). Pelvic ultrasound is useful for early screening, while enhanced CT or MRI aids in diagnosing and evaluating the extent of venous lesions. Complete resection of the lesion is imperative to prevent IVL recurrence. Patients with lesions invading the internal iliac vein and above experience increased intraoperative blood loss and postoperative hospital stays compared to patients with lesions limited to the parauterine/uterine veins. Cases involving lesions in or above the inferior vena cava require a multidisciplinary team approach and may benefit from simultaneous surgery.